TIDMACPH
Correction -- Admission Date for New Ordinary Shares
Included
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US -- 16 December 2021: Acacia
Pharma Group plc ("Acacia Pharma", the "Group" or the "Company")
(EURONEXT: ACPH), a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures or cancer chemotherapy,
was notified on 14 December 2021 that the Company's Employee
Benefit Trust ("EBT") intends to subscribe for 1,145,472 new
ordinary shares in the Company at their par value of 2p each and at
an aggregate cost to the EBT of GBP22,909.44. ("New Ordinary
Shares"). The Company has agreed to lend GBP22,909.44 to the EBT to
fund its subscription for the New Ordinary Shares. The New Ordinary
Shares to be held in the EBT are intended to be used to satisfy
previously announced awards arising from the Company's employee
incentive schemes.
Accordingly, on 16 December 2021, the Company allotted the New
Ordinary Shares to the EBT and such shares will rank pari passu in
all respects with the existing ordinary shares of the Company. The
New Ordinary Shares were admitted to trading on Euronext on 16
December 2021 ("Admission").
Following the issue of the New Ordinary Shares, the Company's
total issued share capital consists of 100,859,423 ordinary shares
with one voting right per share. The Company does not hold any
ordinary shares in treasury. Therefore, following the issue of the
New Ordinary Shares, the total number of voting rights in the
Company is 100,859,423.
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Frazer Hall, Mark Swallow, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 MEDiSTRAVA Consulting
mailto:IR@acaciapharma.com IR@acaciapharma.com +44 20 7638 9571
mailto:acaciapharma@medistrava.com
acaciapharma@medistrava.com
----------------------------------------------- ------------------------------------
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 mailto:chrisvanraemdonck@telenet.be
mailto:ikoffler@lifesciadvisors.com chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
----------------------------------------------- ------------------------------------
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on
the development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures, or cancer chemotherapy.
The Company has identified important and commercially attractive
unmet needs in these areas that its product portfolio aims to
address.
Barhemsys(R) (amisulpride) injection is a selective dopamine (D2
and D3) receptor antagonist approved and available in the US for
the treatment and prevention of postoperative nausea & vomiting
(PONV) in adult patients.
Please see full prescribing information, including Important
Safety Information, at
https://www.globenewswire.com/Tracker?data=FqUdlEo-Y6Sg6jWkazs9E8D0fysiNqhIWvXoD_8yY8rKj--pv1p6xUB-3tGakv6YBSvZpQD-Il1p7VBtQJoi4VwR746QtvoYsNX4nsiOpWWL2kNvteVh2xRiV_GVlf2Hfe-WGq8nrA6YVXFW5jUo7sXAbC5pKRckM2I5n-7thDTskp6gheWIdc6i-t0G-HVUUcHvbLJpi5X_P0PbKRicWqDyuhcRk7uUWoODDD8QsKk=
www.BARHEMSYS.com.
Byfavo(R) (remimazolam) for injection, is an IV benzodiazepine
sedative approved and available in the US for the induction and
maintenance of procedural sedation in adults undergoing procedures
lasting 30 minutes or less. Byfavo is in-licensed from Paion UK
Limited for the US market.
Please see full prescribing information, including Important
Safety Information and Boxed Warning, at
https://www.globenewswire.com/Tracker?data=FqUdlEo-Y6Sg6jWkazs9EykSEaG9dYuZWNAjC8XquWDMj1h9F17pq5TBFqaNI8zzSNP9cxd36n4mIeWzsf0BEcKvsvXP1l2htdGwW7e5JiINmvspvZ6kckP9sZ0_9hZtZweKeqbfKIW1o9dynhI9rAiYzmOQlAVZK4nmVjiGg5OC2ePrSvK0RNnGIR2Mg-B4uyxdfT-_L81VuctxZGD3msjC4TCKqEvgdlswxE9CqDM=
www.BYFAVO.com.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV)
has successfully completed one proof-of-concept and one Phase 2
dose-ranging study in patients receiving highly emetogenic
chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and
its R&D operations are centred in Cambridge, UK. The Company is
listed on the Euronext Brussels exchange under the ISIN code
GB00BYWF9Y76 and ticker symbol ACPH.
This release is intended for investors and media only.
https://www.globenewswire.com/Tracker?data=FqUdlEo-Y6Sg6jWkazs9E_weuXi_Ix6nTsO4OlhIKv9j7i0LfMJfLSzm35pGz-QDK2pe2BWDDkerWgUtuIZW8DOzGehjfu7wWFBnS8inx8c=
www.acaciapharma.com
Forward looking statements
This announcement includes forward-looking statements, which are
based on current expectations and projections about future events.
These statements may include, without limitation, any statements
preceded by, followed by or including words such as "believe",
"expect", "intend", "may", "plan", "will", "should", "could" and
other words and terms of similar meaning or the negative thereof.
Forward-looking statements may and often do differ materially from
actual results. These forward-looking statements are subject to
risks, uncertainties and assumptions about the Company and its
subsidiaries and investments, including, among other things, the
development of its business, trends in its operating industry, and
future capital expenditures and acquisitions. By their nature,
forward-looking statements involve risk and uncertainty because
they relate to future events and circumstances. Any forward-looking
statements reflect the Company's current view with respect to
future events and are subject to risks relating to future events
and other risks, uncertainties and assumptions relating to the
Group's business, results of operations, financial position,
prospects, growth or strategies and the industry in which it
operates. Save as required by law or applicable regulation, the
Company and its affiliates expressly disclaim any obligation or
undertaking to update, review or revise any forward-looking
statement contained in this announcement whether as a result of new
information, future developments or otherwise. Forward-looking
statements speak only as of the date they are made.
(END) Dow Jones Newswires
December 16, 2021 06:18 ET (11:18 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2023 to Mar 2024